Please ensure Javascript is enabled for purposes of website accessibility

Pfizer and BioNTech to Supply WHO's COVID-19 Vaccine Program

By Cory Renauer - Jan 21, 2021 at 7:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The partners could supply the WHO with coronavirus vaccine doses for lower-income countries.

The distribution of coronavirus vaccines in lower-income countries could get a huge boost soon. On Thursday, two sources familiar with the matter told Reuters that Pfizer (PFE -1.83%) and BioNTech (BNTX -1.72%) have agreed to supply a program co-led by the World Health Organization (WHO) with their COVID-19 vaccine.

The COVAX program is a group effort coordinated by the WHO, the Coalition for Epidemic Preparedness Innovations (CEPI), and Gavi, the Vaccine Alliance. The program aims to secure 2 billion doses by the end of this year to protect vulnerable people and frontline healthcare workers in participating countries. All countries are eligible to participate, but the program plans to deliver about 1.3 billion doses to 92 low- and middle-income countries.

A scientist in a laboratory.

Image source: Getty Images.

Details regarding the number of doses Pfizer and BioNTech have agreed to and the price per dose the COVAX program intends to pay the partners are still unclear. Neither company has officially announced an agreement to supply COVAX, but they're expected to fill in the gaps on Friday. 

This won't be the first vaccine authorized in some countries to be secured by the COVAX program. In December, the COVAX program entered an advance purchase agreement with AstraZeneca (AZN -3.53%) for 170 million doses of a coronavirus candidate that has been authorized for use in the U.K. and India. Johnson & Johnson (JNJ -1.86%) also has an agreement with the program to supply 500 million doses of its single-dose vaccine candidate, which is expected to produce late-stage clinical trial data any day now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$50.40 (-1.83%) $0.94
Johnson & Johnson Stock Quote
Johnson & Johnson
$175.50 (-1.86%) $-3.32
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$63.32 (-3.53%) $-2.32
BioNTech SE Stock Quote
BioNTech SE
$157.06 (-1.72%) $-2.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.